Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-MTI-201 in Metastatic Uveal Melanoma
NCT05496686Phase 1Active, not recruiting
- Sponsor
- Modulation Therapeutics
- Start
- Jul 2022
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MTI-201 in Uveal melanoma (UM) (12 arms), sponsored by Modulation Therapeutics. Primary endpoints: Maximum Tolerated Dose at 4 weeks, Dose-Limiting Toxicities at 4 weeks and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
MTI-201
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05496686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496686.